Protagonist TherapeuticsvsThermo Fisher Scientific

PTGX and TMO stock compared: price, dividend, valuation and results, from SEC filings.

PTGX

Protagonist Therapeutics, Inc.

$124.67

Value $8.0B

-4.67%
PTGX's page

TMO

Thermo Fisher Scientific Inc

$686.79

Value $255B

-1.27%
TMO's page

Protagonist Therapeutics (PTGX) has a market value of $8.0B and Thermo Fisher Scientific (TMO) $255B. Over the last year, with dividends, PTGX moved +47.5% and TMO +19.9%. The P/E is 23.2 for PTGX and 36.1 for TMO. Dividend yield: PTGX none, TMO 0.27%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    PTGX$8.0B

    TMO$255B

    TMO is 32 times PTGX

  • Revenue, 12 months

    PTGX$552M

    TMO$47.4B

    TMO is 86 times PTGX

  • Net income, 12 months

    PTGX$342M

    TMO$7.1B

    TMO is 21 times PTGX

  • Operating margin

    PTGX58.6%

    TMO17.9%

    40.7 points apart

  • ROIC

    PTGX33.2%

    TMO8.2%

    25.0 points apart

  • P/E

    PTGX23.2

    TMO36.1

    TMO is 1.6 times PTGX

  • Dividend yield

    PTGX0.0%

    TMO0.3%

    0.3 points apart

  • 5-year return

    PTGX+249.3%

    TMO+10.9%

    238.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

PTGX+249.3%

TMO+10.9%

020040020222023202420252026
Returns by period
PeriodPTGXWith dividendsTMOWith dividends
1 year since November 14, 2025+47.5%Price +47.5%+19.9%Price +19.5%
3 years since November 16, 2023+674.4%+97.8% a yearPrice +674.4%+47.7%+13.9% a yearPrice +46.3%
5 years since November 15, 2021+249.3%+28.4% a yearPrice +249.3%+10.9%+2.1% a yearPrice +9.3%
10 years since November 17, 2016+399.5%+17.5% a yearPrice +399.5%+377.7%+16.9% a yearPrice +364.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

PTGXProtagonist TherapeuticsTMOThermo Fisher Scientific

Valuation

PTGXTMO
Valuation
Price$124.67$686.79
Market value$8.0B$255B
Enterprise value (EV)$7.2B$290B
P/E23.236.1
P/E, 5-year median–32.7
P/B7.34.7
EV/EBIT22.234.3
Free cash flow yield1.4%3.0%

Results and growth

PTGXTMO
Results and growth
Revenue, 12 months$552M$47.4B
Net income, 12 months$342M$7.1B
Free cash flow, 12 months$109M$7.6B
Earnings per share, 12 months$5.36$18.96
Revenue growth, year on year-89.4%3.9%
Revenue growth a year, past+10.0%over 5 years+6.7%over 5 years
EPS growth a year, past–+2.1%over 5 years

Margins and returns on capital

PTGXTMO
Margins and returns on capital
Gross margin––
Operating margin58.6%17.9%
Net margin62.0%14.9%
ROIC33.2%8.2%
ROE44.5%13.4%

Balance sheet

PTGXTMO
Balance sheet
Cash$800M$6.1B
Total debt$8.6M$41.4B
Net debt / EBITDA-2.53.7
Interest cover–5.5×

Dividends and buybacks

PTGXTMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield–1.2%
Shareholder yield–1.5%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: PTGX or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Protagonist Therapeutics or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($255B) is about 32.1 times Protagonist Therapeutics ($8.0B), at today's prices.

How did PTGX and TMO stock do over the last 10 years?

Since November 17, 2016, PTGX's price moved +399.5% and TMO's +364.4%. With dividends: PTGX +399.5% (+17.5% a year), TMO +377.7% (+16.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, PTGX or TMO?

The dividend yield at today's price is none for Protagonist Therapeutics and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

What is the P/E of PTGX and TMO?

At today's price, the P/E is 23.2 for PTGX and 36.1 for TMO. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Protagonist Therapeutics or Thermo Fisher Scientific?

Over the last twelve months, the net margin was 62.0% for Protagonist Therapeutics and 14.9% for Thermo Fisher Scientific, and the operating margin 58.6% and 17.9%. Revenue was $552M and $47.4B.

Which is the better investment, Protagonist Therapeutics or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.